IgGenix
Signal active
Organization
Contact Information
Overview
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
About
Industries
Biotechnology, Health Care, Medical
Founded
2019
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
IgGenix headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $3.6B in funding across 48 round(s). With a team of 1-10 employees, IgGenix is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - IgGenix, raised $40.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
5
Lead Investors
0
Total Funding Amount
$75.0M
Details
4
IgGenix has raised a total of $75.0M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 10.0M | ||
| 2021 | Early Stage Venture | 25.0M | ||
| 2022 | Early Stage Venture | |||
| 2023 | Early Stage Venture | 40.0M |
Investors
IgGenix is funded by 23 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| IgGenix | - | FUNDING ROUND - IgGenix | 40.0M |
| Alexandria Venture Investments | - | FUNDING ROUND - Alexandria Venture Investments | 40.0M |
| IgGenix | - | FUNDING ROUND - IgGenix | 40.0M |
| Sean Parker | - | FUNDING ROUND - Sean Parker | 40.0M |
Recent Activity
There is no recent news or activity for this profile.